Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 16 EP applications Caroline Louise Johnston has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 18, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13168453

Use of alpha-toxin for treating and preventing staphylococcus infections

IPC classification:
A61K 39/40, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP12759083

BIOCONJUGATE VACCINES MADE IN PROKARYOTIC CELLS

IPC classification:
A61K 39/095
Agent:
Jones Day
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14198052

Immunogenic composition

IPC classification:
A61K 39/095, A61K 39/102, A61K 39/116, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
J A Kemp
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13762784

BIOCONJUGATES COMPRISING MODIFIED ANTIGENS AND USES THEREOF

IPC classification:
A61K 39/108, A61K 39/385, A61K 47/48, A61P 31/04
Agent:
Jones Day
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13774455

METHODS OF HOST CELL MODIFICATION

IPC classification:
C12N 1/00
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13788753

PRODUCTION OF RECOMBINANT VACCINE IN E. COLI BY ENZYMATIC CONJUGATION

IPC classification:
A61K 39/09, C12N 15/70
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13815768

METHODS AND COMPOSITIONS RELATING TO CRM197

IPC classification:
A61K 47/48, C07K 14/34, C12N 15/73
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14711232

METHOD OF TREATMENT

IPC classification:
A61K 39/095
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
J A Kemp
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP14727541

IMMUNOGENIC COMPOSITION FOR USE IN THERAPY

IPC classification:
A61K 39/085, A61K 47/48
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15189397

IMMUNOGENIC COMPOSITION

IPC classification:
A61K 39/00, A61K 39/095, A61K 39/102, A61K 39/116, A61K 39/385, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Applicant:
Pfizer Ireland Pharmaceuticals
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Agent:
Pfizer
Status:
GRANT OF PATENT INTENDED
EP14784209

METHODS OF HOST CELL MODIFICATION

IPC classification:
A61K 39/104, C12N 5/10, C12N 15/70, C12N 15/90
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14784210

MODIFIED HOST CELLS AND USES THEREOF

IPC classification:
A61K 39/104, C07K 14/21, C12N 5/10, C12N 15/70
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16193340

IMMUNOGENIC COMPOSITION

IPC classification:
A61K 39/08, C07K 14/33, C12N 15/62
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16192711

IMMUNOGENIC COMPOSITION

IPC classification:
A61K 31/70, A61K 39/085, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15733404

CLOSTRIDIUM DIFFICILE IMMUNOGENIC COMPOSITION

IPC classification:
A61K 39/08, C07K 14/33
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15822948

COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION

IPC classification:
C12N 9/10, C12P 21/00
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Caroline Louise Johnston, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature